Fig. 1

Overexpression of hsa-miR-12462 inhibits the growth of U937 cells and increases cytarabine sensitivity. a Growth rates of U937 wild-type, MOCK-infected, and overexpressing cells (OE vs. MOCK P < 0.0001). b Growth inhibition of wild-type, MOCK-infected, and overexpressing U937 AML cells treated with cytarabine (WT vs. OE P < 0.0001; MOCK vs. OE P < 0.0001). c Growth inhibition of wild-type, MOCK-infected, and overexpressing U937 cells treated with cytarabine at the IC₅₀ of 4 μM (WT vs. OE P < 0.005; MOCK vs. OE P < 0.005). d, e Percent apoptosis of MOCK-infected and overexpressing U937 AML cells treated with cytarabine by FACS analysis (e, OE vs. MOCK P < 0.0001). f Representative histograms of cell cycle phases in MOCK-infected and overexpressing U937 cells by FACS analysis. g The tumor tissues from the xenograft mouse model injected with wild-type (MOCK) and hsa-miR-12462 overexpressing U937 cells (OE). h, i Tumor weights (h) and sizes (i) from mice injected with wild-type and overexpressing U937 cells (MOCK vs. OE 1.11380 ± 0.27820 g vs. 0.16000 ± 0.02266 g, n = 6, P = 0.0057). j Axial anatomic image of mice injected with overexpressing and wild-type U937 cells obtained with 3.0-T MRI. FOV = 64 mm